Biomaterial Database

Second-line treatment in invasive mould infections. 2006

Meinolf Karthaus, and Oliver A Cornely

Medizinische Klinik II, Onkologie und Palliativmedizin, Evangelisches Krankenhaus Bielefeld, Med. Klinik Hämatologie/Onkologie und Palliativmedizin im Johannesstift, Bielefeld, Germany. meinolf.karthaus@evkb.de

A prevalence of up to 30% of invasive fungal infections (IFI) has been reported from autopsy studies in patients treated for haematological malignancies. Despite substantial advances in the last decade, IFI are still associated with a mortality of up to more than 70%, in particular for those patients suffering from invasive aspergillosis. Some progress has been made in diagnostics with the advent of new non-culture based tools and the improvement of imaging techniques. However, the response rates are about 40-60% in the first-line treatment of IFI. Salvage therapy will be necessary for those being intolerant or refractory towards the respective first-line antifungal. Following a long period of stagnation, there has been a considerable progress during the last five years in the treatment of refractory IFI. This review highlights the new treatment options for the salvage setting in the context of the state-of-the-art management of IFI in cancer patients.

UI	MeSH Term	Description	Entries
D009181	Mycoses	Diseases caused by FUNGI.	Fungus Diseases,Fungal Diseases,Fungal Infections,Fungus Infections,Disease, Fungal,Disease, Fungus,Diseases, Fungal,Diseases, Fungus,Fungal Disease,Fungal Infection,Fungus Disease,Fungus Infection,Infection, Fungal,Infection, Fungus,Infections, Fungal,Infections, Fungus
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000935	Antifungal Agents	Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues.	Anti-Fungal Agents,Antifungal Agent,Fungicides, Therapeutic,Antibiotics, Antifungal,Therapeutic Fungicides,Agent, Antifungal,Anti Fungal Agents,Antifungal Antibiotics
D001228	Aspergillosis	Infections with fungi of the genus ASPERGILLUS.	Aspergillus Infection,Aspergilloses,Aspergillus Infections,Infection, Aspergillus,Infections, Aspergillus
D014230	Triazoles	Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3.	Triazole
D016879	Salvage Therapy	A therapeutic approach, involving chemotherapy, radiation therapy, or surgery, after initial regimens have failed to lead to improvement in a patient's condition. Salvage therapy is most often used for neoplastic diseases.	Salvage Treatment,Therapy, Salvage,Salvage Therapies,Salvage Treatments,Therapies, Salvage,Treatment, Salvage,Treatments, Salvage
D016896	Treatment Outcome	Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.	Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes
D020096	Zygomycosis	Infection in humans and animals caused by fungi in the class Zygomycetes. It includes MUCORMYCOSIS and entomophthoramycosis. The latter is a tropical infection of subcutaneous tissue or paranasal sinuses caused by fungi in the order Entomophthorales. Phycomycosis, closely related to zygomycosis, describes infection with members of Phycomycetes, an obsolete classification.	Entomophthoramycosis,Phycomycosis,Entomophthoramycoses,Phycomycoses,Zygomycoses